DANIEL K SPIEGELMAN
CIK 1238403 · EVP, Chief Financial Officer · last filed 2026-06-10
DANIEL K SPIEGELMAN is an EVP, Chief Financial Officer who has filed 144 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing, for MAZE, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$34.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.94M
14
144
-$34.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MAZE | Director | — | $24.05 | — | $0 | 2 | 2026-06-10 |
| SPRB | Director | — | $51.89 | — | $0 | 7 | 2026-05-26 |
| VTVT | Director | — | $32.77 | — | $0 | 2 | 2025-06-12 |
| KYTX | Director | 16,634 | $8.05 | $134.0K | $0 | 1 | 2025-06-02 |
| MYGN | Director | 32,917 | $4.33 | $142.5K | -$792.3K | 11 | 2024-06-07 |
| BMRN | EVP, Chief Financial Officer | 47,686 | $55.95 | $2.67M | -$30.78M | 59 | 2019-06-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 21,006 | — | — | $0 | 4 | 2017-09-26 |
| Relypsa Inc (RLYP) Delisted | Director | 0 | — | — | -$19.6K | 4 | 2016-09-02 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 52,675 | — | — | $33.3K | 17 | 2015-09-28 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 5 | 2013-05-20 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 6 | 2012-06-18 |
| OMER | Director | — | $8.73 | — | $0 | 3 | 2012-06-04 |
| Bio Green Med Solution, Inc. (CYCCP) Delisted | Director | — | $5.05 | — | $0 | 6 | 2012-05-24 |
| CV THERAPEUTICS INC (CVTX) Delisted | SVP, CFO | 74,458 | — | — | -$2.93M | 16 | 2009-04-17 |
Recent Filings
144 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-10 | MAZE | Grant (A) | — | $0 | EDGAR |
| 2026-05-26 | SPRB | Grant (A) | — | $0 | EDGAR |
| 2025-12-15 | SPRB | Mixed | — | $0 | EDGAR |
| 2025-09-24 | MAZE | Grant (A) | — | $0 | EDGAR |
| 2025-07-24 | SPRB | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | VTVT | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | KYTX | Grant (A) | +16,634 | $0 | EDGAR |
| 2024-06-27 | VTVT | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | MYGN | — | — | $0 | EDGAR |
| 2024-06-04 | MYGN | Sell (S) | −7,576 | -$167.0K | EDGAR |